NextPoint Therapeutics discloses $48.7 million private securities offering
A Form D filed with the SEC shows the Cambridge biotech has sold $33.7 million of a planned $48.7 million equity offering to 15 investors.
NextPoint Therapeutics, Inc., a Delaware corporation based in Cambridge, Massachusetts, filed a Form D notice with the Securities and Exchange Commission disclosing a private securities offering. The filing lists a date of first sale of July 22, 2026, and is marked as a new notice rather than an amendment.1
The total offering amount is listed as $48,729,165, with $33,728,772 already sold and $15,000,393 remaining to be sold.1 The company reports 15 investors have already participated in the offering.1
The securities being offered include equity as well as an option, warrant, or other right to acquire another security.1 The offering is being made under the Rule 506(b) exemption.1 The company indicated the offering is not intended to last more than one year.1
NextPoint checked "Decline to Disclose" for both its revenue range and aggregate net asset value range.1 The filing classifies the company's industry as biotechnology within the health care sector.1
Of the gross proceeds, an estimated $2,548,000 is designated for payments to executive officers, directors, or promoters named in the filing.1 The filing states there were no sales commissions or finders' fees associated with the offering.1
Individuals listed in the filing with executive officer or director relationships to the company include Detlev Biniszkiewicz, Ivan Cheung, Axel Hoos, R. Jacob Vogelstein, Brian Shuster, Paulina Hill, Rakhshita Dhar, and Jeffrey Lacey.1 The Form D was signed by Jeffrey Lacey, identified as Secretary and Treasurer, on July 29, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.